Introduction {#Sec1}
============

Urinary bladder cancer (UBC) is the fourth most common malignancy in men and the eighth most common in women, in the Western world \[[@CR1]\]. Approximately 25--30% of bladder tumours are muscle-invasive (MIBC) \[[@CR1], [@CR2]\]. MIBC is associated with high risk of regional and distant metastatic spread, the latter with a median survival of 15 months albeit maximum oncological treatment \[[@CR3]\]. Treatment of localized MIBC (T2a-T4aN0M0) is radical cystectomy (RC) with regional lymphadenectomy (LND). However, despite radical excision, local recurrence or distant metastases develop in around 50% of patients, probably due to early micrometastases \[[@CR4]\]. In attempts to eliminate early dissemination, cisplatin-based combination neoadjuvant chemotherapy (NAC) is recommended to all medically fit patients with clinically localized MIBC \[[@CR5], [@CR6]\]. NAC is administered systemically in 3--4 cycles pre-RC. NAC is associated with significant overall survival (OS) benefits; a large meta-analysis assigned it to an 8% absolute increase in 5-year OS \[[@CR7]\]. Especially good survival benefits have been seen in patients where NAC induces complete downstaging (CD) of the primary tumour, suggesting CD to be a surrogate marker for efficacy on dissemination \[[@CR8]\].

A sentinel node (SN) is defined as the primary tumour-draining lymph node (LN) \[[@CR9]\] and is considered being the primary site of metastasis. Yet, evidence from recent years of SN-research in MIBC shows that the number of detectable SNs often exceed one single node \[[@CR10]--[@CR12]\]. SN-detection (SNd) can be performed by peritumoral injection of radioactive tracer and intraoperative examination with handheld γ-probe \[[@CR11]--[@CR14]\]. Recently, fluorescence-guided intraoperative imaging of lymphatics, using Indocyanine green (ICG) shows promising results \[[@CR15]\].

The SN-concept in MIBC was originally introduced with aims of improving identification of LN-metastases or determining the extent of LN-dissection. However, several studies have shown SN-detection to be of limited or no use in nodal staging \[[@CR12], [@CR14]\]. Instead, focus on SNd in MIBC has shifted to its role in immunobiological research \[[@CR16]--[@CR21]\]. Because a SN is the compartment where the host immune system first encounters tumour-derived antigens, it is also a good site for extracting tumour reactive lymphocytes for use in adoptive T-cell immunotherapy \[[@CR22], [@CR23]\]. Recent SN-research also shows that NAC promotes antitumor T-cell responses in MIBC, by activating T-effector cells (Teffs) and reducing the immunosuppressive activity of regulatory T-cells (Tregs) in SNs. Higher Teff to activated Treg ratio has been established in patients where NAC has induced CD \[[@CR21]\].

What remains unanswered is the relationship between the number of tumour-draining SNs and pathoanatomical responses to NAC. Considering the SN-role in the immune defence against cancer, we speculate that the greater the number of SNs in a patient, the higher the chance of non-progression due to NAC. In 2016 Rosenblatt et al. \[[@CR14]\] reported on the feasibility of SN-detection in NAC-patients, regardless of pT-stage. We now investigate the number of SNs and its association to pathoanatomical status after NAC, in an enlarged prospective cohort.

Materials/patients {#Sec2}
==================

230 patients with suspected urothelial MIBC from ten Swedish urological centers were included in a non-randomized prospective trial. Enrolment started in May 2013 and closed in December 2018. Main inclusion criterion was suspected urothelial MIBC. Reasons for exclusion included; previous BCG-therapy, non-muscle invasive UBC following TURb and robot-assisted laparoscopic radical cystectomy (RARC). For all exclusion criteria, see flow chart (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart of patient inclusions and subgroups. In total, 230 patients were enrolled to undergo TURb for suspected urothelial MIBC. 56 patients were histopathologically diagnosed as non-muscle invasive bladder cancer (NMIBC) and subsequently excluded. 58 patients were excluded due to other reasons, listed in the figure. The remaining patients underwent cystectomy and sentinel node detection (*n* = 116) and was subgrouped according to NAC treatment status. The NAC-patients (*n* = 83) were further stratified into; complete response, CR, (pT0N0M0), stable disease (SD) (pTis-pT4aN0M0), and progressive disease (PD), (pTanyN+ and/or M+)

Methods {#Sec3}
=======

SNd by radioactive technetium was performed in a standardized fashion across all RC-centers as previously described \[[@CR14]\]. A handheld intraoperative Geiger counter registered radioactivity in suspected lymph nodes, by *counts per minute of ionization events (CPM).* Lymph node detection was performed according to the intended same template: Bilateral Obturator fossae, External Iliac artery bilaterally, Common Iliac artery up to mid-level. Any in situ detected sentinel nodes at any other locations were also included apart from the intended template. Nodal specimens were defined by histopathology as true LNs or not. A true LN, w/wo metastasis, with detected CPM ≥ 10 was defined as a *SN*. If a nodal SN-specimen was found containing \> 1 LN in the pathology evaluation, the detected CPM-value was divided by the number of contained nodes. Specimens with CPM \> 10 not containing any lymphatic tissue, were *false positive (FP)-*detections. If an undetected specimen showed LN-metastasis, it was named a *false negative (FN)*-detection.

Statistics {#Sec4}
----------

Differences in numerical and ordinal variables were tested using one-way ANOVA. For categorical data, the Chi-squared test was used. Furthermore, selected covariates were analyzed in a multivariate linear model for possible confounders impacting SN-yield. Statistical analyses were performed in IBM SPSS 25 and 26.

Results {#Sec5}
=======

116 patients underwent RC and SNd (fig) and of these, 83 patients received 1--4 cycles of NAC and were stratified by pathoanatomical outcomes, into *complete response* (*CR*), (pT0N0M0), *stable disease (SD)* (pTis-pT4aN0M0) and *progressive disease (PD)* pTanyN+ and/or pM+ (Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristicsNACNo NACAllAll NACCR---complete responseSD---stable diseasePD---progressive disease*p*valueDesignation of outome--pT0N0M0pTis-T4aN0M0pTanyN+All pT-stages--No. of patients8336351233116Age (mean)6766.869.30.6175.869.7Age (range)39--8039--7939--7958--8057--8739--87Gender0.91 Male66 (79.5)28 (77.8)28 (80)10 (83.3)19 (57.6)85 (73.3) Female17 (20.5)8 (22.2)7 (20)2 (16.7)14 (42.4)31 (26.7)Clinical stage0.04 cT263 (75.9)32 (88.9)24 (68.6)7 (58.3)23 (69.7)86 (74.1) cT317 (20.5)4 (11.1)8 (22.9)5 (41.7)10 (30.3)27 (23.3) cT4a3 (3.6)03 (8.6)003 (2.6)No. of NAC-cycles0.86 16 (7.2)3 (8.3)2 (5.7)1 (8.3) 29 (10.8)1 (2.8)6 (17.1)2 (16.7) 362 (74.7)30 (83.3)24 (68.6)8 (66.7) 46 (7.2)2 (5.6)3 (8.6)1 (8.3)NAC-type0.89 MVAC25 (30.1)11 (30.5)11 (31.4)3 (25) HD-MVAC53 (63.9)24 (66.7)21 (60)8 (66.7) Cisplatin-gemzar4 (4.8)1 (2.8)2 (5.7)1 (8.3) Carboplatin-gemzar1 (1.2)01 (2.9)0Baseline characteristics for all 116 cystectomized patients distributed over subgroups. Statistical analysis was applied on NAC-patients only. There were no statistical differences between NAC-subgroups in age, gender, number of NAC-cycles or NAC-type. NAC-subgroups differed significantly in clinical tumour stage pre-RC (*p* = 0.04)*NAC*neoadjuvant chemotherapy, *RC*radical cystectomy, *HD-MVAC*high dose Methorexate, Vinblastine, Adriamycin, Cisplatin

In the NAC-treated cohort, clinicopathological factors were compared between the subgroups. There were no statistical differences in age, gender or number of NAC cycles (Table [1](#Tab1){ref-type="table"}). The pathoanatomical outcomes in the NAC-treated cohort (*n* = 83), were CR in 43.4% (36/83), SD in 42.2% (35/83) and PD in 14.4% (12/83) (Table [2](#Tab2){ref-type="table"}). NAC-subgroups differed significantly in clinical tumour stage pre-RC, with a higher number of cT3 and cT4 tumours in SD and PD-patients (*p* = 0.04). Interestingly, there were significant differences in mean and median number of SNs per patient in CR and SD compared to PD (*p* = 0.034). The SN-detection rate was 91.7% in CR-patients and 58.3% in PD-patients (Table [3](#Tab3){ref-type="table"}). There were higher FP-detection rates in CR-patients (36.1%), compared to the overall FP-detection rate of 29.3% (*p* = 0.36) (Table [3](#Tab3){ref-type="table"}). However, in a multivariate linear regression model, the only significant predictor for SNs was the number of harvested nodes (Table [4](#Tab4){ref-type="table"}).Table 2Pathoanatomical outcomesFinal pTNMNACNo NACAllCR---complete responseSD---stable diseasePD---progressive diseasepT0N0M0**36**00**642**pTisN0M00**5**00**5**pTaN0M00**2**00**2**pT1N0M00**5**0**16**pT2N0M00**11**0**415**pT3N0M00**10**0**1020**pT4aN0M00**2**0**13**pT0N+00**1**0**1**pTisN+00**1**0**1**pT2N+00**4**0**4**pT3N+00**5712**pT4aN+00**123**pT4bN+000**11**Any M+000**11**Final pTNM-stages post-cystectomy for all included patients, stratified by subgroups. In the NAC-treated cohort; Complete Response (CR) was found in 43.4% (36/83), Stable Disease in 42.2% (35/83) and Progressive Disease in 14.4% (12/83) of the patientsTable 3True positive and false positive sentinel node detectionsNACNo NACAllAll NACCR---complete responseSD---stable diseasePD---progressive disease*p*valueTotal no of harvested lymph nodes13506165721625081858Mean no of harvested lymph nodes16.317.116.313.50.515.416Sentinel nodes Total26212012517102364 Mean3.23.33.61.4**0.034**3.13.1 Median22.431**0.049**32.5 Rate of detection %85.591.788.658.375.882.8False positive nodes Total42251341860 Mean0.510.690.370.330.360.550.52 Rate of detection %30.136.122.933.327.329.3Total and mean number of harvested lymph nodes, true sentinel nodes and false positive detections, for all cystectomized patients and by subgroups. A true positive detection was defined as a radioactive specimen with \> 10 CPM confirmed as a lymph node by histopathology. Detections with CPM \> 10 which did not contain any lymphatic tissue, were labelled as false positive (FP). There was a significant difference in both mean and median number of SNs between the NAC-subgroups (*p* = 0.034 and *p* = 0.049)*CPM*counts per minute (measured by Geiger probe intraoperatively), *CR*complete response, *SD*stable disease, *PD*progressive disease, *NAC*neoadjuvant chemotherapyTable 4Factors impacting SN-yieldPredictorsTrue SNsMultivariate *p*valueAge0.18Gender0.67Total no harvested nodes**0.0004**No. of NAC-cycles0.47The total number of harvested lymph nodes was the only statistically significant predictor of SN yield*RC* radical cystectomy, *NAC*neoadjuvant chemotherapy

Discussion {#Sec6}
==========

In the present study, we saw that the mean and median number of sentinel nodes (SN) were significantly lower in patients with progressive disease. This is, to our knowledge, the first time an association between SN yield and pathological outcome in NAC-treated MIBC, is recorded.

The finding could be explained by previous observations, namely that metastatic deposits appear to block lymph vessels or redirect the lymphatic flow resulting in a lowered rate of SN detection in patients with more advanced disease \[[@CR11]\]. In addition, the biological role of the lymphatic system could be considered. These vessels are not passive venues for mechanical spread of cancer cells, but rather they play a major role in tumor immune responses \[[@CR24], [@CR25]\]. A recent experimental study showed that mice with ablated lymphatics exhibited reduced intra-tumoral accumulation of cytotoxic T cells and increased tumor PD-L1 expression, causing rapid tumor growth. Additionally, impaired function of the peritumoral lymphatic vessels resulted in decreased migration of dendritic cells to draining SNs compared with normal flank skin-draining lymph nodes \[[@CR26]\].

Therefore, we hypothesize that the condition of the lymphatics might be reflected in the SN status. Conversely, a deficient lymphatic system could imply a state of immunodeficiency, which can result in reduced responsiveness to chemotherapy \[[@CR21]\]. Thus, *the number of SNs* could hypothetically be a surrogate marker for antitumoral immunological activity, and perhaps, responsiveness to NAC.

Nevertheless, the association between the number of SNs and pathoanatomic outcomes must be interpreted with caution. For instance, the only factor that impacted the yield of SNs in our multivariate analysis was the total number of harvested lymph nodes. Several limitations of the study must be taken into consideration: First, the study is a retrospective analysis of a prospective cohort, meaning that the material was stratified and analyzed according to post-hoc constructed groups. Second, there were many centers with relatively few patients per center. This runs the risk of introducing bias due to heterogeneity in terms of individual urologic surgeons and pathologists. For example, individual lymph node dissection practices could theoretically cause variations in the LND template, since the template was predefined but not explicitly controlled for. Third, the time between injection of radioactive tracer and performed SNd may have varied by hours between patients, this due to intraoperative difficulties or different surgical techniques. A prolonged operation, allows the tracer to increasingly disperse throughout the entire lymphatic drainage line, leading to a suboptimal SNd. Fourth, peritumoral injections of technetium comes with technical challenges, especially in cases of large localized tumours or tumours located in diverticulae. For the fifth, the CPM-registration can be difficult to interpret. In some cases, there would be one reading in the surgical field but another on the dissection table.

With the approval of check-point inhibitors in late-stage urinary bladder cancer, there is a need to find good predictive markers for successful immunotherapy. In the future, patients with less advanced and non-disseminated tumours will probably undergo check-point inhibition. The main precondition for successful check-point inhibition is the very presence of active anti-tumourally directed T effector cells. A significantly reduced amount of T effector cells might indicate less efficacy of that kind of immunotherapy. Hence, a high number of sentinel nodes may be a candidate marker of mounted and functional immune responses valuable for adjuvant immunological therapy.

Conclusions and future perspectives {#Sec7}
===================================

There was a significant difference in mean and median numbers of SNs after NAC, between patients with CR and SD compared to PD-patients, with a significantly lower number of SNs in patients with progressive disease. However, many factors impact the SN-yield. We hypothesize that the number of SNs might reflect the function of the regional lymphatic system, thus making SN-number a plausible surrogate marker for antitumoral immunological activity.
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This research involved human participants and all included patients have given their written and oral informed consent to participate. Inclusion was performed in two steps, for the first step---prior to TURb, all patients gave their informed consent as above stated. For the second step, patients proceeding to radical cystectomy, informed consent as above, was repeated.
